Discovery Lens
C Combination Innovation
Two separate worlds finally connect — and the intersection is a product
One-Liner
Continuous volume measurement and shrinkage attribution technology from petroleum tank gauging applied to restaurant and bar beverage inventory.
AI Thinking Process
Verb Transplant from petroleum tank gauging: continuous ultrasonic volume measurement with shrinkage attribution (evaporation, theft, line loss). Destination: restaurant and bar beverage inventory. Petroleum gauging is highly mature and precise — same physics applies to liquor bottles.
Competitive search on destination: BarVision — continuous pour measurement via bottle sensors, exact same verb. BeverageMetrics — inventory shrinkage attribution for bars. AccuBar — automated bar inventory with volume tracking. All are funded, operational, and at scale. The verb is not absent from the destination; it exists under different product names.
KILLED: verb already exists in destination. BarVision is the petroleum-tank-gauging verb applied to bars. This is the G160-type failure mode: Verb Transplant requires checking for the verb's existing instantiations in the destination under different names. No pivot attempted — category is saturated.
Kill Reason
The verb (continuous volume measurement with shrinkage attribution) already exists in the destination as BarVision, BeverageMetrics, AccuBar — all 5+ funded competitors doing exactly this with different sensors.
Risk Analysis
Risk analysis available for latest engine ideas.
Loading...
Related ideas you can explore free:
killed: Passive voice-based depression detection requires FDA Software as a Medical Device clearance for any diagnostic claim; a "wellness" framing undercuts the core value proposition and reduces willingness to pay. Epic Systems and large telehealth platforms are already integrating validated mental health screening tools into clinical workflows, crowding out standalone apps before they achieve scale.
killed: Google Nest Hub's built-in Soli radar-based sleep sensing already delivers contactless respiratory monitoring in millions of households, and Withings has shipped FDA-cleared sleep apnea screening hardware. A standalone $30 WiFi module cannot match the distribution, brand trust, or regulatory standing of these well-resourced incumbents.
killed: Urine and stool analysis for glucose monitoring, cancer screening, and kidney function markers falls squarely into FDA Class II/III medical device territory, requiring clinical trials and 510(k) or PMA approval costing millions and taking years. The entire high-value use case — the reason anyone would buy this — is legally undeliverable without regulatory clearance the product cannot realistically obtain.